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n	 INTRODUCTION
Tumor necrosis factor alpha (TNFα) antagonists showed their efficacy and 
safety in controlling disease signs and 
symptoms of ankylosing spondylitis (AS) 
(1). The concept of disease remission plays 
a relevant role in the management of AS, 
representing a major treatment target that 
should consider different aspects of the 
disease, including extra-articular mani-
festations, i.e. psoriasis, inflammatory 
bowel disease (IBD), uveitis, and acute 
phase reactants (2). Owing to the lack of 
definition of the differentiation between 
complete clinical remission and a status of 
The objective of this study was to evaluate the predictive factors for achieving partial remission (PR) in patients 
with ankylosing spondylitis (AS) treated with anti-TNFα. We longitudinally enrolled in a multi-center study 
214 AS patients, classified according to New York criteria, treated with anti-TNFα drugs adalimumab (ADA), 
etanercept (ETA) and infliximab (INF) with at least 12 months of follow up. PR was reached when the score 
was <20 mm (on a visual analogue scale of 0-100 mm) in each of the following 4 domains:
1) patient global assessment (in the last week);
2) pain (spinal pain);
3) function [measured by the bath ankylosing spondylitis functional index (BASFI)];
4) inflammation [mean of intensity and duration of morning stiffness, from the bath ankylosing spondylitis 
disease activity index (BASDAI)].
Two hundred fourteen AS patients (M/F=160/54; median age/range=43.2/19-78 years; median disease dura-
tion/range=96/36-189 months) were treated with ADA (15.8%), ETA (28.9%) and INF (55.1%). At 12 and 24 
months, high serum level of C reactive protein (CRP) (≥2 vs ≤0.8 mg/dL) were associated with higher rate of 
PR in AS patients treated with anti-TNFα drugs. At 24 months, PR was associated with shorter disease duration 
(≤36 vs ≥189 months) and higher erythrosedimentation rate (ESR) values (≥45 vs ≤17 mm/h). In male patients 
lower bath ankylosing spondylitis metrology index (BASMI) (≤2 vs ≥6) and absence of psoriasis were associat-
ed with higher PR rate only at 12 months. Other parameters assessed before treatment, such as BASDAI, BAS-
FI, peripheral arthritis, inflammatory bowel disease and uveitis were not associated with PR. Our long-term 
longitudinal study in a setting of clinical practice showed that inflammatory parameters (i.e. CRP, ESR) and 
disease duration represent the most important predictive variables to achieve PR with an anti-TNFα treatment.
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low disease activity, the Ankylosing Spon-
dylitis Assessment Study (ASAS) working 
group proposed a score for the definition 
of partial remission (PR) (3). PR could be 
reached in 20-40% of AS patients treated 
with anti-TNFα drugs, as demonstrated in 
randomized controlled trials and in clinical 
practice experiences (4-10). Furthermore, 
evidence derived from randomized trials 
and national registries showed that demo-
graphic, clinical and laboratory factors, 
i.e. C reactive protein (CRP), age, the Bath 
ankylosing spondylitis functional index 
(BASFI), enthesitis and HLA-B27, could 
be predictors of a better clinical response 
after the introduction of anti-TNFα therapy 
(11-14). The aim of this study was to evalu-
ate the predictive factors for achieving PR 
in a large cohort of AS patients treated with 
adalimumab (ADA), etanercept (ETA) and 
infliximab (INF) in a real-life clinical set-
ting.
n	 MATERIALS AND METHODS
A longitudinal observational study was 
performed in 6 secondary referral rheuma-
tologic Italian centers (Roma, Campobas-
so, Milano, Padova, Potenza and Reggio 
Emilia).
We studied 214 AS patients, classified ac-
cording to New York criteria (15), treated 
with TNFα antagonist with a follow-up pe-
riod ranging from 12 to 24 months. ADA 
(40 mg every two weeks) and ETA (25 mg 
twice a week or 50 mg once a week) were 
administered subcutaneously; INF was ad-
ministered intravenously at 3-5 mg/kg at 
0-2-6 weeks, then every 6-8 weeks. All pa-
tients signed an informed consent accord-
ing to the Declaration of Helsinki and the 
design of the study was approved by the lo-
cal ethical committee (La Sapienza Univer-
sity of Rome). At the beginning of the anti-
TNFα treatment, the main demographic, 
clinical, laboratory and radiological char-
acteristics of each AS patients, including 
gender, age, disease duration, clinical pat-
tern (axial with or without peripheral ar-
thritis), extra-articular manifestations (i.e. 
psoriasis, IBD, uveitis), HLA-B27 typing 
and X-ray sacroiliitis grade according to 
the New York criteria (15) were collected. 
Bath ankylosing spondylitis metrology in-
dex (BASMI) (16), Bath ankylosing spon-
dylitis disease activity index (BASDAI) 
(17), BASFI (18), the patient’s visual ana-
logue scale (VAS) of 0-100 mm on disease 
activity and overall spinal pain, the number 
of tender and swollen joints, and labora-
tory parameters such as erythrosedimenta-
tion rate (ESR) and CRP were evaluated at 
baseline and after 12 and 24 months from 
anti-TNFα treatment initiation. PR was 
reached when the score was <20 mm (on a 
VAS of 0-100 mm) in each of the following 
4 domains:
1) patient global assessment (in the last 
week);
2) pain (spinal pain);
3) function (measured by the BASFI); 
inflammation (mean of intensity and 
duration of morning stiffness, from the 
BASDAI) (2, 19).
The association of PR with the main vari-
ables at baseline was studied. In particu-
lar, continuous variables (i.e. age, disease 
duration, CRP, ESR, BASDAI, BASMI, 
BASFI) were analyzed by comparing the 
different quartiles.
All anti-rheumatic treatments, including 
disease modifying anti-rheumatic drugs 
(DMARDs), steroids, non-steroidal anti-
inflammatory drugs (NSAIDs) and comor-
bidities were recorded. The reasons for 
discontinuation were classified as lack of 
efficacy, adverse event, or other reasons. 
The definition of lack of effectiveness was 
based on a clinical evaluation according to 
ASAS/European League Against Rheuma-
tism (EULAR) recommendations for the 
management of AS (20).
Statistical analysis
Categorical variables were analyzed using 
the χ-square test with Yates correction or 
the Fisher exact test. Association of pre-
dictor variables with ASAS partial remis-
sion was explored using an odds ratio (OR) 
with a 95% confidence interval (CI). OR 
was interpreted as: 1.5 to 1 weak associa-
tion; 2.5 to 1 moderate association; 4 to 1 
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association. The results were expressed as 
median/25th-75th percentile. P values <0.05 
were considered significant.
n	 RESULTS
The main demographic, clinical and labora-
tory features of AS patients (n=214) treated 
with TNFα blockers (ADA=34, ETA=62, 
INF=118) at baseline are shown in Table I. 
Among the 214 patients, the anti-TNFα 
treatment was still administered to 203 
(94.8%) at 12 months and to 158 (73.9%) 
at 24 months. 
During the follow up, the overall rate of 
discontinuation of anti-TNFα drug was 
9.3% (n=20), including 11 patients (5.1%) 
who stopped the drug due to loss of effec-
tiveness, 5 (2.3%) patients due to adverse 
events and 4 (1.8%) for other reasons. 
ADA, ETA, and INF were discontinued 
due to loss of effectiveness in 4 (1.8%), 1 
(0.4%) and in 6 (2.8%), patients respec-
tively. 
PR rates at 12 and 24 months during treat-
ment with ADA, ETA and INF in patients 
with AS are shown in Figure 1. 
The PR rate was not significantly differ-
ent among all anti-TNF-α (ADA, ETA 
or INF). During the two-year study, 131 
(61.2%) patients reached PR. In particular, 
113 (86.2%) patients reached PR within 
12 months from the beginning of the anti-
TNFα therapy.
The association of a PR response with the 
main variables at baseline in AS treated 
with ADA, ETA and INF at 12 and 24 
months of follow up is shown in Table II. 
In particular, the continuous variables (i.e. 
age, disease duration, CRP, ESR, BASDAI, 
BASMI, BASFI) were analyzed by com-
paring the different quartiles (Table II). 
At 12 and 24 months, high serum levels of 
CRP (≥2 vs ≤0.8 mg/dL), were associated 
with a higher PR rate in AS patients treated 
with anti-TNFα drugs. At 24 months, PR 
was associated with shorter disease dura-
tion (≤36 vs ≥189 months) and higher ESR 
values (≥45 vs ≤17 mm/h). Male sex, lower 
BASMI (≤2 vs ≥6) and absence of psoriasis 
were associated with higher PR rate only at 
Table I - Demographic, clinical and laboratory fe-
atures of ankylosing spondylitis patients (n=214) 
treated with TNFα blockers at baseline. 
Male (%) 74.8
Median age; years (median/25th-75th 
percentile) 
43.2/34-54
Median disease duration; months 
(median/25th-75th percentile) 
96/36-189
Presence of HLA-B27 (%) 62.6
CRP mg/dL (median/25th-75th 
percentile)
1.4/0.8-2.8
ESR mm/I h (median/25th-75th 
percentile)
30/17-45
BASDAI (median/25th-75th percentile) 5.9/4.8-6.5
BASMI (median/25th-75th percentile) 3/2-4.9
BASFI (median/25th-75th percentile) 5.4/4.1-6.6
Presence of grade IV sacroiliitis (%) 33.1
Presence of peripheral arthritis (%) 49.5
Presence of psoriasis (%) 11.6
Presence of IBD (%) 11.6












Figure 1 - Partial remission rates in ankylos-
ing spondylitis patients receiving anti-TNFα 
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12 months. Other parameters assessed be-
fore treatment, such as BASDAI, BASFI, 
peripheral arthritis, IBD and uveitis, were 
not associated with PR. 
n	 DISCUSSION
A state of remission or inactive disease is 
the main objective in chronic inflammatory 
conditions such as AS (4). Several studies 
showed that the widespread use of anti-
TNFα drugs could induce a state of clinical 
remission in about 20-40% of AS patients. 
In our observational study, in a setting of 
clinical practice, we confirmed high rate of 
PR in AS patients who started anti-TNFα 
treatment with ADA, ETA and INF. In 
particular, PR was achieved in 50.4% and 
48.6% of AS patients treated with anti-
TNFα after 12 and 24 months of follow 
up, respectively. The PR rate with ADA, 
ETA or INF was not significantly different 
among all anti-TNFα patients.
Table II - Odds ratio (OR) and 95% confidence intervals (CI) of partial remission response in ankylosing 









Gender Male vs female 2.05 (1.09-3.84) 0.02 1.3 (0.60-3.04) n.s.
Age (years) ≤34 vs >34 - ≤43 2.01 (0.78-5.18) n.s. 2.16 (0.79-5.92) n.s.
≤34 vs >43 - <54 1.49 (0.65-3.40) n.s. 1.22 (0.42-3.50) n.s.
≤34 vs ≥54 2.01 (0.90-4.47) n.s. 2.44 (0.94-6.30) n.s.
Disease duration 
(months)
≤36 vs >36 - ≤96 0.76 (0.34-1.65) n.s. 1.85 (0.58-5.87) n.s.
≤36 vs >96 - <189 0.81 (0.35-1.84) n.s. 2.08 (0.62-6.99) n.s.
≤36 vs ≥189 1.58 (0.73-3.41) n.s. 5 (1.59-15.6) 0.005
HLA-B27 Absence vs presence 0.86 (0.46-1.63) n.s. 1.31 (0.57-2.98) n.s.
CRP (mg/dL) ≥2 vs >0.8 - ≤1.5 0.82 (0.39-1.70) n.s. 1.19 (0.48-2.93) n.s.
≥2 vs >1.5 - <2 1.69 (0.65-4.42) n.s. 2.38 (0.73-7.83) n.s.
≥2 vs ≤0.8 2.44 (1.21-4.93) 0.03 3.39 (1.43-8.04) 0.005
ESR (mm/h) ≥45 vs >17 - ≤30 1.46 (0.66-3.25) n.s. 1.47 (0.49-4.33) n.s.
≥45 vs >30- <45 1.96 (0.88-4.35) n.s. 2.38 (0.86-2.53) n.s.
≥45 vs ≤17 1.63 (0.73-3.62) n.s. 3.06 (1.14-8.15) 0.02
BASDAI ≤4.8 vs >4.8 - ≤5.9 1.25 (0.55-2.79) n.s. 0.8 (0.27-2.31) n.s.
≤4.8 vs >5.9 - <6.5 1.36 (0.60-3.06) n.s. 0.77 (0.19-2.56) n.s.
≤4.8 vs ≥6.5 2.08 (0.93-4.64) n.s. 2.17 (0.84-5.58) n.s.
BASMI ≤2 vs >2 - ≤3 1.65 (0.65-3.71) n.s. 2.3 (0.78-4.70) n.s.
≤2 vs >3 - <6 1.64 (0.83-3.21) n.s. 1.59 (0.65-3.24) n.s.
≤2 vs ≥6 3.44 (1.28-9.11) 0.01 3.06 (0.89-10.5) n.s.
BASFI ≤4.5 vs >4.5 - ≤5.5 0.84 (0.41-1.75) n.s. 0.48 (0.19-1.23) n.s.
≤4.5 vs >5.5 - <6.5 0.65 (0.29-1.44) n.s. 0.40 (0.14-1.09) n.s.
≤4.5 vs ≥6.5 1.32 (0.64-2.70) n.s. 0.88 (0.38-2.70) n.s.
Sacroiliitis (grade IV) Absence vs presence 1.39 (0.76-2.56) n.s. 1.42 (0.67-2.97) n.s.
Peripheral arthritis Absence vs presence 1.47 (0.84-1.55) n.s. 0.63 (0.32-1.25) n.s.
Psoriasis Absence vs presence 2.46 (0.98-6.16) 0.05 2.18 (0.79-6) n.s.
IBD Absence vs presence 0.7 (0.29-1.71) n.s. 0.75 (0.25-2.23) n.s.
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Our experience in a clinical practice set-
ting, confirmed previous results that high 
serum level of CRP were associated with a 
higher rate of PR in AS patients treated with 
anti-TNFα drugs (14). In fact, ASSERT 
and GO-RAISE trial data were analyzed 
to identify baseline predictors for various 
disease-state and disease-activity outcome 
instruments in AS (14). In this study CRP, 
together with age, BASFI score, enthesi-
tis, therapy and HLA-B27 genotype, was 
identified as a predictor variable with se-
lected outcome instruments, including 
ASAS PR at six months (14). These results 
are in keeping with other studies showing 
that CRP was associated to BASDAI 50 re-
sponse (12, 21). 
Moreover, in our study the evidence that 
high ESR (≥45 mm/h) had a predictive 
value supports that this inflammation pa-
rameter could be considered an alterna-
tive in cases where CRP is not available, 
according to the use of AS disease activ-
ity score (ASDAS) with CRP or ESR (22). 
The strong association of short disease du-
ration (≤36 months) with PR confirmed the 
results of Rudwaleit et al., who analyzed 
factors associated to clinical response 
BASDAI 50 in two clinical trials on ETA 
and INF (21). 
This association could be an important is-
sue in order to suggest an early treatment 
intervention. Furthermore, in our study 
we found that patients with lower BASMI 
(≤2) before starting an anti-TNFα therapy 
had a higher PR rate compared with pa-
tients with higher BASMI score (≥6). This 
metrology parameter, even in the absence 
of inflammatory activity, could influence 
the domains of PR, such as BASFI and 
the patient global assessment, reducing 
the probability of achieving a remission 
status. In our study, the presence of grade 
IV sacroiliitis did not affect the PR rate. 
These results suggest that the TNFα treat-
ment could be useful also in patients with 
severe axial involvement according to the 
efficacy of ADA in AS patients with a 
total spine ankylosis (23). Female sex is 
considered a risk factor for functional dis-
ability, but its predictive value for clinical 
response to anti-TNFα in AS has not been 
reported (24). In our study a weak evi-
dence of association of male gender with 
PR was demonstrated only at 12 months. 
In our study, other baseline variables (i.e. 
age, HLA-B27, BASDAI, BASFI and pe-
ripheral involvement) did not affect the 
PR rate. The weak association of BAS-
DAI with PR could be due to the inclusion 
criteria giving a homogeneous selection 
of patients based on elevated BASDAI 
scores. Among extra-articular manifes-
tations, the predictive value of psoriasis 
with a good clinical response to anti-
TNFα drugs is still debated (5, 24, 25). In 
our experience, the presence of psoriasis 
at baseline evaluation was associated with 
a lower PR rate after 12 months of anti-
TNFα therapy. 
Some discrepancies of our results with 
previous studies can be explained by a dif-
ferent definition of cut-off levels of puta-
tive predictive variables, different outcome 
measures, study designs and follow-up pe-
riods. 
In particular, it has to be emphasized that 
observational studies might yield different 
findings from those coming from random-
ized controlled trials. 
A limitation of this study was the lack of 
magnetic resonance imaging (MRI) of 
sacroiliac joints and spine, but in our ex-
perience, based on clinical practice, the 
availability of MRI was not mandatory for 
recruitment. 
MRI is actually the cornerstone of the clas-
sification of non-radiographic axial spon-
dyloartritis and some studies showed the 
ability of anti-TNFα to reduce the presence 
and extension of the inflammatory lesion 
on MRI. Furthermore, other experience 
demonstrated the predictive value of bone 
marrow edema to achieve clinical response 
to anti-TNFα both in patients with SA and 
non-radiographic axial spondyloarthritis 
(26, 27). 
In conclusion, our long-term study in a 
setting of clinical practice showed that 
inflammatory parameters (i.e. CRP, ESR) 
and disease duration represent important 
predictive variables to achieve PR with 
anti-TNFα treatment, irrespective of dam-
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